Huaota's antibody drug discovery platform encompasses high-throughput automated hybridoma technology, single B cell screening technology, and nanobody screening technology, supporting multifaceted antibody drug research and development.

Antibody optimization technologies include antibody humanization, affinity maturation, and Fc engineering to extend half-life. We conduct in vivo and in vitro efficacy evaluations and druggability assessments at early project stages, performing comprehensive evaluations of antibody drugs through a well-established new drug research system.

Huaota's antibody drug discovery platform has been successfully applied to the R&D of multiple innovative drugs, efficiently and qualitatively enriching the drug pipeline, with the aim of providing solutions for unmet clinical needs.

The company possesses an innovative monoclonal/multispecific antibody R&D platform (SynerBody®) based on AI-assisted and structure-based design: leveraging a diverse fully human antibody screening technology to build a molecular parts library, supplemented by commercial AI-assisted evaluation of molecular druggability, with experimental data as the core basis for judgment, successfully generating high-yield long-acting antibodies and supporting multiple pipeline candidates advancing to clinical stages.

Huaota has independently developed the HOTAC™ (Huaota Optimized Technology of Antibody Conjugate) ADC platform, a comprehensive technology system encompassing four core modules—antibody, linker, conjugation technology, and payload. The company holds complete independent intellectual property rights across the entire ADC development chain.

Antibody Module: The platform flexibly incorporates monoclonal antibodies and nanobodies to develop multi-epitope/multispecific antibodies. Through affinity optimization, antibodies are endowed with superior antigen specificity and synergistic effects, expanding the boundaries of ADC molecular design.

Linker Module: Our proprietary linkers are specifically cleaved by cathepsin B or β-glucuronidase, enabling conditional release within the tumor microenvironment. They combine high hydrophilicity with excellent plasma stability, remaining stable in circulation and releasing the cytotoxic payload only within tumor cells, thereby minimizing off-target toxicity to normal cells.

Conjugation Technology Module: The platform has established a diverse conjugation system covering cysteine-based random/site-specific conjugation and glycan-directed site-specific conjugation, achieving highly homogeneous products. By integrating multiple conjugation technologies, we have innovatively developed dual-payload ADC technology.

Payload Module: We have developed a diversified next-generation toxin payload portfolio, including novel topoisomerase I inhibitors and first-in-class payloads (N-myristoyltransferase inhibitors, DNA damage repair inhibitors, molecular glues, etc.). Our proprietary payloads exhibit enhanced bystander killing effects and cell membrane permeability, effectively overcoming tumor resistance.

Leveraging a differentiated next-generation payload portfolio, we mitigate the risk of resistance commonly associated with existing ADC drugs. The HOTAC™ platform works in deep synergy with the company's AI-assisted, structure-based innovative monoclonal/multispecific antibody discovery platform, continuously generating ADC candidates with clinical trial application potential.

The Drug Substance Manufacturing Workshop of Shanghai Huaota Biopharmaceutical Co., Ltd. covers an area of approximately 870 m², with a clean area of 727 m². The workshop is primarily composed of seed culture room, fermentation room, purification room, ultrafiltration room, media preparation room, and other auxiliary functional areas. Key equipment, including single-use mixing systems, bioreactors, and chromatography columns, are sourced from world-class suppliers such as Cytiva, PALL, and Sartorius. The facility supports cell culture scale-up up to 1,000 L.

The Drug Product Manufacturing Workshop covers an area of 700 m², with a clean area of 578 m², comprising washing and sterilization room, unpacking room, filling room, media preparation room, and others. Equipment includes a pulsating vacuum sterilizer, a prefilled syringe filling line (Bosch system, with a production capacity of 17,000 units/hour), and a vial filling line (Bosch system, with a production capacity of 12,000 units/hour).